Results 1 to 10 of about 30,461 (170)
Revista Española de Quimioterapia, 2021 Ceftazidime is a 3rd generation cephalosporin active against Pseudomonas aeruginosa. Avibactam is an inhibitor of class A, C and some class D β-lactamases. The antibacterial spectrum of ceftazidime-avibactam covers 95% of P. aeruginosa isolates and >99% of enterobacteria, including strains carrying extended-spectrum β-lactamases (ESBLs).
Matesanz, Mayra, Mensa, José
openaire +3 more sources
Revista Española de Quimioterapia, 2022 The increase in nosocomial infections by beta-lactamase producing Gram-negative bacilli constitutes a therapeutic challenge. The combination of ceftazidime-avibactam offers a very interesting therapeutic option for nosocomial pneumonia caused by extended-spectrum beta-lactamase-producing Klebsiella pneumoniae, multidrug-resistant Pseudomonas aeruginosa,
F. Herrero
openaire +3 more sources
In silico ADME and Toxicity Prediction of Ceftazidime and Its Impurities
Frontiers in Pharmacology, 2019 To improve the quality control of drugs, we predicted the absorption, distribution, metabolism, excretion, and toxicity (ADMET) of ceftazidime (CAZ) and its impurities via in silico methods.
Ying Han +5 more
doaj +2 more sources
Antimicrobial Agents and Chemotherapy, 2017 Ryan K Shields, Liang Chen, Yohei Doi
exaly +2 more sources
Ceftazidime-avibactam in ceftazidime-resistant infections [PDF]
The Lancet Infectious Diseases, 2016 One of the important causes of the development of resistance to β-lactam drugs is their overuse. β-lactamase inhibitors have been combined with many β-lactam drugs to resume their efficacy since the emergence of multidrugresistant organisms. Yahuda Carmeli and colleagues recommended the combination of ceftazidimeavibactam as a potential alternative to ...
Yehuda, Carmeli +4 more
openaire +5 more sources
Antimicrobial Agents and Chemotherapy, 2022 First variants of the Klebsiella pneumoniae carbapenemase (KPC), KPC-2 and KPC-3, have encountered a worldwide success, particularly in K. pneumoniae isolates.
C. Hobson +7 more
semanticscholar +1 more source
Synergistic Activity of Three Iranian Medicinal Plants in Combination with Ceftazidime and Neomycin against Bacterial Strains Causing Nosocomial Infections [PDF]
Research Journal of Pharmacognosy, 2022 Background and objectives: This study aimed to investigate the antimicrobial properties of Salvia limbata, Centella asiatica, and Bacopa Monnieri extracts against Staphylococcus aureus, Pseudomonas aeruginosa, Acinetobacter baumannii and methicillin ...
Fatemeh Tavakoli* +3 more
doaj +1 more source
The Use and Effectiveness of Ceftazidime–Avibactam in Real-World Clinical Practice: EZTEAM Study
Infectious Disease and Therapy, 2023 Introduction Ceftazidime–avibactam has proven activity against multidrug-resistant (MDR) bacteria in clinical trials and real-world studies. This study was conducted to describe the patterns of use of ceftazidime–avibactam (including indications and ...
Á. Soriano +22 more
semanticscholar +1 more source
European Journal of Clinical Microbiology and Infectious Diseases, 2023 Introduction Ceftazidime/avibactam-resistance in Klebsiella pneumoniae carbapenemase-producing Klebsiella pneumoniae (KPC-Kp) is a topic of great interest for epidemiological, diagnostic, and therapeutical reasons.
M. Boattini +8 more
semanticscholar +1 more source
Ceftazidime resistance in Pseudomonas aeruginosa is multigenic and complex
PLoS ONE, 2023 Pseudomonas aeruginosa causes a wide range of severe infections. Ceftazidime, a cephalosporin, is a key antibiotic for treating infections but a significant proportion of isolates are ceftazidime-resistant.
K. Ramsay +7 more
semanticscholar +1 more source